R. Hector MacKay-Dunn KC

Practice Areas

Mergers & Acquisitions;

Corporate Finance & Securities;

Corporate & Commercial;

Mining Law;

Information Technology;

Private Client Services

Professional Memberships

Member of the Law Societies of British Columbia, Alberta & Ontario;

Member of the Canadian, American and International Bar Associations

Experience

Senior partner Hector MacKay-Dunn, KC, has 30+ years of experience providing advice to high-growth public and private companies and public institutions, over a broad range of industry sectors including life sciences, technology, health, mining and clean tech, advising on corporate domestic and cross-border public and private securities offerings, M&A, international partnering & licensing transactions, large-scale long-term infrastructure services projects and to boards of directors and independent board committees on corporate governance matters. Along with Chambers 2023, Hector is recognized in the Lexpert Special Editions – Finance and M&A, Technology and Mining; in The Best Lawyers in Canada in the areas of biotech, M&A, securities and technology and holds the AV Preeminent rating from Martindale-Hubbell. Hector received the BC Life Sciences Milton Wong Leadership Award) and King’s Counsel (BC) designation. Hector has served as board member with a number of private and public companies and the board of the BC Tech Association, Chair of the BC Innovation Council and Genome BC and the board and executive of Tennis Canada. Hector is admitted to the BC, Alberta, and Ontario Bars.

Work Highlights

Counsel to Mind Cure Health Inc. in its business combination transaction with LNG Energy Holdings Inc;

Counsel to Canexia Health, an innovator in genomics-based cancer testing, on its merger with Artificial Intelligence healthcare company Imagia Cybernetics. The merger included a $20 million funding with participation from BDC Capital’s Women in Technology Venture Fund, Desjardins Capital, and PacBridge Capital;

Counsel to the Provincial Health Ministry and Provincial Health Authority on a Long term (11 year) Master Medical Laboratory Services Agreement between Provincial Health Ministry and Provincial Health Authority and a private sector service provider for community laboratory medical testing and related services;

Counsel to Copper Fox Metals Inc. in numerous private placement equity financings and its flow through equity investment in District Copper Corp;

Canadian Counsel to Arbutus Biopharma Corporation with respect to the sale of part of its royalty interest on future global net sales of ONPATTRO™ (patisiran), an RNA interference (RNAi) therapeutic to OMERS, the defined benefit pension plan for municipal employees based in the Province of Ontario, Canada; Canadian Counsel to Arbutus Biopharma Corporation and the Arbutus Special Committee with respect to closing of a US$116 million Strategic Investment from Roivant Sciences; Canadian Counsel to Arbutus Biopharma Corporation in a US$50 million At-the-Market equity program; Counsel to the Special Committee of the Board of Directors of Pacific Insight Electronics Inc. in its sale to Methode Electronic; Canadian Counsel to Arbutus Biopharma Corporation and the Arbutus Special Committee in launching Genevant Sciences with industry-leading platform to develop a broad range of RNA Therapeutics for genetic diseases; Canadian Counsel to Tekmira Pharmaceuticals Corporation in a merger of equals with OnCore Biopharma, Inc. creating an industry-leading therapeutics solutions company focused on developing a cure for chronic hepatitis B virus; Amgen Inc., Biovail Laboratories International SRL and MedGenesis Therapeutix Inc. global license agreements and collaboration agreement between Biovail and MedGenesis and related equity investment by Amgen Inc. in MedGenesis, for development of GDNF for an undisclosed amount; Acquisition of Can Test Ltd., British Columbia’s largest independent analytical laboratory business, for an undisclosed price, by Maxxam Analytics International Corporation, a company majority owned by OMERS Administration Corporation; US $915 million acquisition of Aspreva Pharmaceuticals Corporation, by Galenica Group under which Galenica, through a wholly-owned Canadian subsidiary, will acquire all of Aspreva’s outstanding shares for cash.

Publications

The Best Lawyers in Canada (2024);

Chambers Canada Ranked Lawyers (2023);

Lexpert Leading Lawyers in Canada (2023);

Lexpert Leading Technology and Health Sciences Lawyers (2023);

Lexpert Leading Mining Lawyers (2023);

Lexpert Leading Finance and M&A Lawyers (2023)

Career

Called to British Columbia Bar, 1978

Education